36
Participants
Start Date
October 4, 2022
Primary Completion Date
September 12, 2024
Study Completion Date
September 12, 2024
BMS-986442
Specified dose on specified days
Nivolumab
Specified dose on specified days
Docetaxel
Specified dose on specified days
Carboplatin
Specified dose on specified days
Pemexetred
Specified dose on specified days
Paclitaxel
Specified dose on specified days
Local Institution - 0018, Darlinghurst
Local Institution - 0001, Westmead
Local Institution - 0002, Clayton
Local Institution - 0086, Southport
Local Institution - 0084, Murdoch
Local Institution - 0064, Candiolo
Local Institution - 0046, Allentown
Local Institution - 0065, Milan
Local Institution - 0083, Madrid
Local Institution - 0079, Madrid
Carolina BioOncology Institute, Huntersville
Local Institution - 0082, Málaga
Mayo Clinic in Florida, Jacksonville
Local Institution - 0027, Orlando
Local Institution - 0087, Seville
Local Institution - 0019, Cincinnati
Local Institution - 0081, Valencia
Local Institution - 0029, Fort Wayne
Local Institution - 0005, Grand Rapids
Local Institution - 0077, Siena
Mayo Clinic in Rochester, Minnesota, Rochester
Local Institution - 0022, New Orleans
Local Institution - 0016, Houston
Local Institution - 0062, Napoli
Mayo Clinic in Arizona - Phoenix, Phoenix
Local Institution - 0069, Bydgoszcz
Local Institution - 0096, Costa Mesa
Local Institution - 0075, Orange
Local Institution - 0003, Hackensack
Local Institution - 0067, Warsaw
Local Institution - 0073, Gdansk
Local Institution - 0080, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY